Stryker Corporation (SYK)vsCatheter Precision Inc. (VTAK)
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
VTAK
Catheter Precision Inc.
$1.20
+0.84%
HEALTHCARE · Cap: $3.05M
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 4185900% more annual revenue ($25.12B vs $600,000). SYK leads profitability with a 12.9% profit margin vs 0.0%. VTAK trades at a lower P/E of 0.1x. SYK earns a higher WallStSmart Score of 65/100 (C+).
SYK
Buy65
out of 100
Grade: C+
VTAK
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Margin of Safety
+99.2%
Fair Value
$228.68
Current Price
$1.20
$227.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 128.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bull Case : VTAK
The strongest argument for VTAK centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 128.0% demonstrates continued momentum.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : VTAK
The primary concerns for VTAK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
SYK profiles as a value stock while VTAK is a hypergrowth play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.87 — expect wider price swings.
VTAK is growing revenue faster at 128.0% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 38/100) and 11.4% revenue growth. VTAK offers better value entry with a 99.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Catheter Precision Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?